Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Sustainability and cost-avoidance of reduced inappropriate red cell transfusion at community hospitals in niagara region: A follow-up analysis on a quality improvement initiative.

Alexis Fang, Hasan Rana, Asif Khowaja et al. Nov 03, 2025 pp. 4388-4388 10.1182/blood-2025-4388

Abstract Introduction: Red blood cell transfusions (RBC) are a vital component of medical treatment in Canada. Yet, RBC units are expensive...

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Lindsay Rein, Firas El Chaer, Junichiro Yuda et al. Nov 03, 2025 pp. 2018-2018 10.1182/blood-2025-2018

Abstract Background: PIM1 is overexpressed in hematologic malignancies, including myelofibrosis (MF), contributing to disease progression by...

Real-world experience of efanesoctocog alfa in Hemophilia A patients in the US: A retrospective analysis

Sibgha Zaheer, Nina Hwang, Kyle Davis et al. Nov 03, 2025 pp. 1286-1286 10.1182/blood-2025-1286

Abstract Introduction Efanesoctocog alfa is a first-in-class, high-sustained factor VIII (FVIII) replacement therapy designed to overcome th...

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)

Pierre Morel, Christian Buske, Alexander Grunenberg et al. Nov 03, 2025 pp. 223-223 10.1182/blood-2025-223

Abstract Beside Rituximab-Bendamustine, the Dexamethasone, Rituximab and Cyclophospamide (DRC) regimen is still one of the most frequently u...

Q- hemegenome: The Qatar national registry for germline predisposition to myeloid and other hematologic malignancies

Amna Gameil, Mariem Sidenna, Huda Farah et al. Nov 03, 2025 pp. 7951-7951 10.1182/blood-2025-7951

Abstract Background Recognition of germline predisposition to myeloid and other hematologic malignancies has increased substantially in rece...

Machine learning replicates and extends clinician-informed disease severity grading classification for acute pain and CKD in sickle cell disease

Minzhang Zheng, Joseph Wardell, Renee Hodges et al. Nov 03, 2025 pp. 4733-4733 10.1182/blood-2025-4733

Abstract Acute pain and chronic kidney disease (CKD) are two of the most serious and phenotypically variable complications in sickle cell di...

Enteral supplementation with a TGF-β-enriched polymeric diet mitigates gastrointestinal acute gvhd

Sangya Chatterjee, Lena Riegler, Ina Martin et al. Nov 03, 2025 pp. 4081-4081 10.1182/blood-2025-4081

Abstract Gastrointestinal acute graft-versus-host disease (GI-aGVHD) is a major contributor to non-relapse mortality after allogeneic hemato...

Reveal-MM: Retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma – a US claims-based case-control study

Faith Davies, Beth Faiman, Hayley Beer et al. Nov 03, 2025 pp. 4569-4569 10.1182/blood-2025-4569

Abstract Introduction Multiple myeloma (MM) presents with non-specific symptoms, often leading to diagnostic delays or mis-referrals to vari...

Proportion of second hematologic malignancies linked to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries 2001-2022

Rupayan Kundu, Sneha Singh, Niladri Kal et al. Nov 03, 2025 pp. 4637-4637 10.1182/blood-2025-4637

Abstract Introduction: Radiotherapy is a cornerstone of cancer treatment, known to improve local tumor control and survi...

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents

Natalie Boytsov, Molly Purser, Richard Zur et al. Nov 03, 2025 pp. 7922-7922 10.1182/blood-2025-7922

Abstract Introduction: Costs associated withadministration and adverse events (AEs) are important considerations in budget impact models (BI...

Integrative surfaceome mapping in AML identifies CD85d as an immunotherapy target

Omar Ibrahim, Michael Rettig, Reyka Jayasinghe et al. Nov 03, 2025 pp. 338-338 10.1182/blood-2025-338

Abstract Adoptive immunotherapies have transformed the treatment landscape for several hematologic malignancies, yet their clinical impact i...

Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09

Michael Jordan, Franco Locatelli, Didier Halimi et al. Nov 03, 2025 pp. 4758-4758 10.1182/blood-2025-4758

Abstract Introduction: Primary hemophagocytic lymphohistiocytosis (pHLH) is a life-threatening, genetically driven, interferon-γ (IFNγ)–medi...

Association between absolute eosinophil count and outcomes in sickle cell disease

Grace Ferri, Rachel Anderson, Omar El Fadel et al. Nov 03, 2025 pp. 6512-6512 10.1182/blood-2025-6512

Abstract Objective: Patients with sickle cell disease (SCD) may experience vaso-occlusive episodes (VOE) requiring hospitalization. Studies...

The oral PI3Kdelta inhibitor Linperlisib and Obinutuzumab as response-dependent, first-line regimen for marginal zone lymphoma: A prospective single-arm Phase Ib/II Study

Jia Li, Xingtong Wang, Wei Guo et al. Nov 03, 2025 pp. 7099-7099 10.1182/blood-2025-7099

Abstract Introduction Indolent non-Hodgkin lymphomas, such as marginal zone lymphoma (MZL), typically follow an indolent course and are asso...

Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia

Victoria Rogness, Bharath Dileep Kumar, Chingiz Underbayev et al. Nov 03, 2025 pp. 5653-5653 10.1182/blood-2025-5653

Abstract Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy characterized by clonal exp...

Survival outcomes of adolescents and young adults with lymphoblastic lymphoma treated with pediatric-inspired protocols in the Middle East

Sarah Altayyari, Amr Hanbali, Ahmed Kotb et al. Nov 03, 2025 pp. 6846-6846 10.1182/blood-2025-6846

Abstract Lymphoblastic lymphoma (LBL) is a highly aggressive neoplasm of precursor lymphoid cells, accounting for approximately 2% of all no...

Haploidentical hematopoietic stem cell transplantation with bussulfan, fludarabine and cyclophosphamide and total body irradiation 200cgy conditioning with post-transplant cyclophosphamide and peripheral blood stem cells as an alternative regimen to reduce graft rejection in sickle cell disease

Roberto Silva, Lucas Silva, Clarissa Melo et al. Nov 03, 2025 pp. 7724-7724 10.1182/blood-2025-7724

Abstract Background: Sickle cell disease (SCD) is a hereditary hemoglobinopathy affecting millions worldwide, characterized by chronic hemol...

ATR inhibition with nucleoside analog therapy synergistically overcomes chemoresistance and reprograms dark zone lymphomas toward immune-accessible phenotypes

Allison SY Chan, Phuong Hoang, Akshaya Anbuselvan et al. Nov 03, 2025 pp. 1536-1536 10.1182/blood-2025-1536

Abstract Introduction: Dark zone-like diffuse large B-cell lymphoma (DZ-DLBCL) represents a distinct germinal center B-cell (GCB) subtype, c...

Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma

Cecilia Bonolo de Campos, Kuo Chien Daniel Lee, Ruijuan He et al. Nov 03, 2025 pp. 3316-3316 10.1182/blood-2025-3316

Abstract We previously reported achemo-genomics screen that unexpectedly identified phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) as a...

Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)

Trishtha Agarwal, Teja Sureddi, Nagateja Yedida et al. Nov 03, 2025 pp. 7437-7437 10.1182/blood-2025-7437

Abstract Background: The treatment landscape of chronic lymphocytic leukemia (CLL) has shifted with the adoption of targeted therapies admin...

TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated Acute Myeloid Leukemia

Alexandra Schurer, Humaira Ilyas, Maxim Maron et al. Nov 03, 2025 pp. 869-869 10.1182/blood-2025-869

Abstract Mutations in nucleophosmin (NPM1) are identified in 35% of acute myeloid leukemia (AML) patients, but therapeutic strategies target...

Pentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas

Cristian Taborda, Iris Isufi, Tarsheen Sethi et al. Nov 03, 2025 pp. 2433-2433 10.1182/blood-2025-2433

Abstract Background: Aggressive T-cell lymphomas are rare, biologically heterogeneous malignancies with a poor prognosis in the relapsed or...

Impact of pre-existing cardiovascular disease on inpatient arrhythmias following autologous stem cell transplantation in multiple myeloma: A national inpatient sample database analysis

Hector Garcia Pleitez, Nehemias Guevara, Chanokporn Puchongmart et al. Nov 03, 2025 pp. 4022-4022 10.1182/blood-2025-4022

Abstract Introduction: Autologous stem cell transplantation (ASCT) continues to be a cornerstone in the treatment of eligible patients with m...

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Sandeep Raj, Allison Bock, Sharmila Giri et al. Nov 03, 2025 pp. 3748-3748 10.1182/blood-2025-3748

Abstract Background: Despite the promising efficacy of CAR-T for patients with relapsed or refractory (R/R) large B-cell lymphomas (LBCL), mo...

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Ali Bazarbachi, Mathilde Fekom, Maria Carmen Martinez Munoz et al. Nov 03, 2025 pp. 4521-4521 10.1182/blood-2025-4521

Abstract Introduction: Autologous hematopoietic stem cell transplantation (auto-HSCT) remains a standard of care for patients with chemosens...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page